Ercin, Seval MüzeyyenÇalık Başaran, NurselAladağ, Murat2021-03-242021-03-242020ERCİN S. M,BAŞARAN N. Ç,ALADAĞ M (2020). Evaluation of the Effectiveness of Tenofovir in Chronicm Hepatitis B Patients. Acta Medica, 51(1), 9 - 14. Doi: 10.32552/0.ActaMedica.4232147-9488https://doi.org/10.32552/0.ActaMedica.423https://hdl.handle.net/11616/19713https://search.trdizin.gov.tr/yayin/detay/378776Abstract: Objectives: HBV infection is a global public health problem. Tenofovir disoproxil fumarate and tenofovir alafenamide are nucleotide reverse transcriptase inhibitors and used for the treatment of chronic Hepatitis B infection. The aim of this study was to evaluate treatment response and efficacy of Tenofovir disoproxil fumarate. Materials and Methods: The study included hepatitis B positive patients who started to use Tenofovir disoproxil fumarate. We retrospectively reviewed electronic medical files of Hepatitis B patients. Hepatitis B surface antigen, Hepatitis B surface antibody, Hepatitis B e antigens, Hepatitis B e antibody, Hepatitis B viral DNA, aspartate aminotransferase, alanine aminotransferase values were evaluated in the 1st, 3rd, 6th, 9th, and 12th months. Result: None of the patients under Tenofovir disoproxil fumarate treatment was “primary resistant”. Alanine aminotransferase normalization at 12th month was seen in 80.4% of study population. Hepatitis B surface antigen seroconversion was detected only in one patient (0.85%) at 9th months and Hepatitis B e antigen seroconversion was observed in 9 patients (8.3%) under Tenofovir disoproxil fumarate treatment. At the sixth month of Tenofovir disoproxil fumarate treatment, complete response was found in 77 (65.8%), partial response in 21 (18%) and inadequate response were in 19 (16.2%). Among Hepatitis B e antigen positive patients, 44 (80 %) patients had undetectable Hepatitis B virus DNA levels at the end of 12th month and among Hepatitis B e antigens negative patients, 52 (91.2%) patients had undetectable Hepatitis B DNA levels at the end of 12th month (p<0.01). Conclusion: Among patients with chronic HBV infection, Tenofovir disoproxil fumarate had satisfying antiviral efficacy. There is no primary resistance in patients treated with Tenofovir disoproxil fumarate. Patients had statistically significant improvement in aspartate aminotransferase, alanine aminotransferase, Hepatit B virus DNA levels.eninfo:eu-repo/semantics/openAccessArticle51191410.32552/0.ActaMedica.423378776